METTL3 functions as the catalytic core in the methyltransferase complex,[50] and there is growing interest in small‐molecule inhibitors targeting METTL3 for potential cancer treatments.[18] By analyzing RIP‐seq data, we predicted the m6A motif in the IRF1 transcript, which was verified through MeRIP–qPCR (Figure 6A,B). Here, IRF1 is linked to cancer.